Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.

Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N.

J Mol Med (Berl). 2013 Apr;91(4):459-72. doi: 10.1007/s00109-012-0958-0. Epub 2012 Sep 30.

PMID:
23052481
2.

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN.

Mol Immunol. 2005 Jul;42(11):1311-9. Epub 2005 Apr 7.

PMID:
15950727
3.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

PMID:
25711293
4.

Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.

Raguénez G, Mühlethaler-Mottet A, Meier R, Duros C, Bénard J, Gross N.

BMC Cancer. 2009 Mar 30;9:97. doi: 10.1186/1471-2407-9-97.

5.

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.

Siebert N, Seidel D, Eger C, Jüttner M, Lode HN.

PLoS One. 2014 Sep 16;9(9):e107692. doi: 10.1371/journal.pone.0107692. eCollection 2014.

6.

Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.

Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Bogenmann E, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):151-5. Review.

PMID:
12880975
7.
8.

In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.

Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Montaldo PG, Gambini C, Allen TM, Bogenmann E, Ponzoni M.

Int J Cancer. 2003 May 1;104(5):559-67.

9.

Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.

Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN.

J Immunol Methods. 2013 Dec 15;398-399:51-9. doi: 10.1016/j.jim.2013.09.008. Epub 2013 Sep 18.

PMID:
24055592
10.

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS.

J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x.

11.

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1996 Dec;2(12):1951-9.

12.

Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.

Siebert N, Eger C, Seidel D, Jüttner M, Lode HN.

J Immunol Methods. 2014 May;407:108-15. doi: 10.1016/j.jim.2014.04.001. Epub 2014 Apr 12.

PMID:
24727144
13.

Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.

Chen NE, Maldonado NV, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP.

Mol Cancer Ther. 2016 Nov;15(11):2653-2664. Epub 2016 Aug 16.

PMID:
27530131
14.

Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.

Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA.

Cancer Res. 1991 Jan 1;51(1):144-9.

15.

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC.

Clin Cancer Res. 2013 Apr 15;19(8):2132-43. doi: 10.1158/1078-0432.CCR-12-1243. Epub 2013 Feb 1.

16.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
17.

Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.

Kawashima I, Yoshida Y, Taya C, Shitara H, Yonekawa H, Karasuyama H, Tada N, Furukawa K, Tai T.

Int J Oncol. 2003 Aug;23(2):381-8.

PMID:
12851687
18.

The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.

Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H.

Cancer Lett. 2009 Aug 28;281(2):171-82. doi: 10.1016/j.canlet.2009.02.040. Epub 2009 Mar 31.

PMID:
19339105
19.

GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide.

Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M.

Int J Cancer. 1999 Apr 12;81(2):268-74.

20.

Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

Brignole C, Pastorino F, Marimpietri D, Pagnan G, Pistorio A, Allen TM, Pistoia V, Ponzoni M.

J Natl Cancer Inst. 2004 Aug 4;96(15):1171-80.

PMID:
15292389

Supplemental Content

Support Center